Global Oncology Companion Diagnostics Market Projected to Surpass $6.21 Billion by 2029 with 13% Annual Growth

What Are the Market Size and Growth Forecast for the Oncology Companion Diagnostics Market?
The size of the oncology companion diagnostics market has seen a swift expansion in recent years. The market which was worth $3.35 billion in 2024 is projected to grow to $3.8 billion in 2025, registering a compound annual growth rate (CAGR) of 13.4%. The rise in the historic period is a result of factors such as the growing instances of adverse drug reactions, the escalating demand for extensive genomic testing, the increasing global prevalence of cancer, the heightened need for targeted therapy, and an increase in the number of clinical trials.

In the upcoming years, a significant surge is anticipated in the size of the oncology companion diagnostics market. The prediction indicates a leap to $6.21 billion in 2029, following a compound annual growth rate (CAGR) of 13.0%. The leap in the predicted period is tied to the growing significance of personalized medicine, a rise in diagnostic tests, an increased emphasis on tailored cancer therapy, burgeoning healthcare spending, and a rise in cancer incidence and awareness. Noteworthy trends expected in the forecast period encompass advancements in diagnostic technologies, the evolution of next-generation sequencing (NGS), the incorporation of artificial intelligence (AI), the burgeoning field of liquid biopsy technologies, the advent of point-of-care companion diagnostic tools, and the innovation of testing technologies.

What Key Elements Are Boosting Growth in the Oncology Companion Diagnostics Market?
The anticipated increase in cancer incidents is poised to fuel the expansion of the oncology companion diagnostics market. Being a multifaceted cluster of diseases caused by aberrant cells growing and spreading uncontrollably in the body, cancer's rise can be attributed to alterations in lifestyle, ecological aspects, the obesity crisis, tobacco consumption, and genetic contributors. Oncology companion diagnostics play a crucial role in fine-tuning oncology treatments by introducing precision medicine. This approach revolutionizes cancer care by tailoring treatment options, augmenting treatment effectiveness, reducing negative impacts, aiding in clinical trial participation, and boosting treatment surveillance measures. For example, the National Cancer Institute, a government agency based in the US, reported roughly 20 million new cases and 9.7 million cancer-related deaths annually in May 2024, documenting the statistics from 2022. Predictions suggest that by 2040, the annual numbers would ascend to 15.3 million deaths and 29.9 million new instances. Consequently, the escalation in cancer incidences propels the growth of the oncology companion diagnostics market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15623&type=smp

Which Key Market Leaders Are Driving Oncology Companion Diagnostics Industry Growth?
Major companies operating in the oncology companion diagnostics market are F. Hoffmann-La Roche AG, Bayer Diagnostic, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, BGI Genomics Co. Ltd., Natera Inc., Myriad Genetics Inc., ARUP Laboratories, NeoGenomics Laboratories Inc., Guardant Health, Ambry Genetics Corporation, Biocartis SA, CENTOGENE N.V., Invivoscribe Inc., Pillar Biosciences Inc.

What Are the Emerging Trends in the Oncology Companion Diagnostics Industry?
Leading firms in the oncology companion diagnostics market are prioritizing the creation of innovative products such as in vitro diagnostic tests to secure their market standing. Often known as IVD tests, these are clinical examinations conducted on samples like blood or tissue collected from the human body and tested outside the body in a regulated environment such as a lab. For example, in May 2022, biotechnology company Illumina Inc., based in the US, introduced a new pan-cancer companion diagnostic (CDx) indication to the in-vitro diagnostic TruSight Oncology (TSO) Comprehensive (EU) test. This diagnostic tool offers an extensive tumor profile by assessing multiple tumor genes and biomarkers, giving healthcare experts the data they need to make informed decisions about targeted treatment for cancer patients with solid malignant neoplasms. This test offers essential insights, like the tumor mutational burden (TMB) score and microsatellite instability (MSI) status, increasing the accuracy and efficacy of treatment plans.

What Are the Main Segments in the Oncology Companion Diagnostics Market?
The oncology companion diagnostics market covered in this report is segmented -

1) By Product: Instrument, Consumables, Software
2) By Disease Type: Melanoma, Breast Cancer, Colorectal Cancer, Leukemia, Prostate Cancer, Other Disease Types
3) By Technology: Immunohistochemistry (IHC), In Situ Hybridization (ISH) Or Fluorescence In Situ Hybridization (FISH), Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
4) By End User: Hospital, Pathology Or Diagnostic Laboratory, Academic Medical Center, Other End-Users

Subsegments:
1) By Instrument: Polymerase Chain Reaction (Pcr) Instruments, Next-Generation Sequencing (Ngs) Systems, Immunohistochemistry (Ihc) Instruments, Fluorescence In Situ Hybridization (Fish) Instruments, Microarray Platforms
2) By Consumables: Reagents And Kits (Dna Or Rna Extraction Kits, Pcr Reagents), Biopsy Needles, Testing Slides And Chips, Control And Calibration Samples
3) By Software: Data Analysis Software, Bioinformatics Software ( For Gene Expression Analysis), Companion Diagnostic Decision Support Software, Clinical Workflow Management Software

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Which Geographic Area Leads the Oncology Companion Diagnostics Market?
North America was the largest region in the oncology companion diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology companion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Oncology Companion Diagnostics Global Market Report?

- Market Size Analysis: Analyze the Oncology Companion Diagnostics Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Oncology Companion Diagnostics Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Oncology Companion Diagnostics Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Oncology Companion Diagnostics Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15623

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.